Climb Bio, Inc. (CLYM) · Sep 3, 2026 · Other events
Above the bar — ~29-day half-life; 60-75% IgA/Gd-IgA1 suppression through 12 weeks
CLYM116 delivers a 29-day half-life and durable APRIL suppression, strengthening the Q12W thesis. Patient efficacy data remain ahead.
The direction was partly expected, but the magnitude is the news. Climb Bio had already disclosed favorable initial safety data and previewed this September 3 PK/PD readout, so the event itself was anticipated; no conventional published numerical consensus was available for this early-stage clinical update.
The Phase 1 pharmacology clears the key development hurdle. A single 320 mg dose produced more than 90% free APRIL suppression and roughly 60-75% suppression of IgA, Gd-IgA1, and IgM maintained through 12 weeks.
| Measure | CLYM116 result | Comparison / implication |
|---|---|---|
| Half-life | ~29 days | ~3x longer than sibeprenlimab (Key Data and Highlights) |
| Free APRIL suppression | >90% after one 320 mg dose | Supports durable target suppression (Key Data and Highlights) |
| IgA, Gd-IgA1, and IgM suppression | ~60-75% | Maintained through 12 weeks (Key Data and Highlights) |
| Safety | No serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia | Favorable early safety profile (Key Data and Highlights) |
The result strengthens the every-12-week commercial and clinical thesis. The approximately 29-day half-life is materially better than the prior sibeprenlimab benchmark, while the sustained biomarker suppression gives the company a credible basis to take the Q12W regimen into registrational development. 〔0〕
This is still a PK/PD win, not an efficacy readout. The 46-subject Phase 1 study enrolled healthy volunteers and was designed around safety, pharmacokinetics, and pharmacodynamics rather than kidney outcomes in IgA nephropathy patients. 〔1〕
Net: clearly better than the standing bar, with the decisive test still ahead. The filing upgrades confidence in CLYM116's dosing convenience, biological durability, and competitive positioning, but NAVIGATE-2 must show that these biomarker effects translate into meaningful IgAN outcomes. Initial Phase 2 data are expected in the first half of 2027, while further Phase 1 and partner data are due in the fourth quarter of 2026. 〔2〕
Additional Phase 1 data, Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!